8-KRegulation FDOther EventsExhibits & Filings

ALTRIA GROUP, INC. 8-K Report, Regulation FD Disclosure (Mar 6, 2023)

Filed March 6, 2023For Securities:MO

Summary

Altria Group, Inc. (MO) has announced two significant strategic moves related to the e-vapor market, signaling a shift in its product portfolio. First, the company has exchanged its minority economic investment in JUUL Labs, Inc. for a global license to JUUL's heated tobacco intellectual property. This move effectively disentangles Altria from its previous substantial investment in JUUL while acquiring valuable technology rights. Concurrently, Altria has agreed to acquire NJOY Holdings, Inc., a prominent e-vapor product company, for approximately $2.75 billion in cash, with potential additional payments of up to $500 million tied to FDA approvals. This acquisition aims to secure full global ownership of NJOY's e-vapor product line, notably including the NJOY ACE, which holds FDA market authorizations. These transactions collectively demonstrate Altria's strategic intent to strengthen its position in the evolving e-vapor and heated tobacco landscape.

Key Highlights

  • 1Altria exits its minority economic investment in JUUL Labs, Inc.
  • 2Altria secures a global license to JUUL's heated tobacco intellectual property.
  • 3Altria agrees to acquire NJOY Holdings, Inc. for approximately $2.75 billion in cash.
  • 4Potential for an additional $500 million in cash payments to NJOY sellers contingent on FDA approvals.
  • 5Acquisition provides Altria with full global ownership of NJOY's e-vapor product portfolio.
  • 6NJOY ACE, a key product in the acquisition, is the only pod-based e-vapor product with FDA market authorizations.

Frequently Asked Questions

Altria will record the financial impact of the JUUL transaction in the first quarter of 2023. The details of this impact, including any gains or losses recognized, will be reflected in their upcoming financial statements.

Altria will acquire NJOY through a merger for approximately $2.75 billion in cash at closing. There is an additional $500 million in cash contingent on certain NJOY products receiving FDA approvals. The acquisition is subject to customary closing conditions and is not dependent on financing.

The NJOY ACE is highlighted as the only pod-based e-vapor product with market authorizations from the U.S. Food and Drug Administration (FDA). This regulatory approval is a significant competitive advantage and de-risks Altria's entry into this segment of the e-vapor market.

The company notes several risks, including the potential failure to receive regulatory authorizations for NJOY products, non-compliance with regulatory requirements, failure to realize the expected benefits of the merger, adverse changes in economic or market conditions, and the outcome of any legal proceedings related to the merger.